يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"intercellular adhesion molecule 1 antibody"', وقت الاستعلام: 0.44s تنقيح النتائج
  1. 1

    المصدر: Repositorio EdocUR-U. Rosario
    Universidad del Rosario
    instacron:Universidad del Rosario

    مصطلحات موضوعية: Brain antigen, 0301 basic medicine, Unclassified drug, Mouse, N methyl dextro aspartic acid receptor antibody, Apoptosis, Pathogenesis, Disease, Bioinformatics, Neuroendocrine system, Animals, Genetically Modified, Dietary supplement, Mice, Autoantibody, 0302 clinical medicine, Pathology, Lupus vasculitis, Medicine, Biological therapy, animal, Priority journal, P 140 peptide, Systemic lupus erythematosus, Vaccination, Lupus Vasculitis, Central Nervous System, genetically modified, Cardiolipin antibody, Animal models, Neuropsychiatric systemic lupus erythematosus, Transgenic animal, Blood brain barrier, N methyl dextro aspartic acid receptor nr2 antibody, Cytokines, Complement inhibitor, Human, Disease onset, medicine.drug_class, Complement, Genetic predisposition to disease, Lupus, Neuropsychiatric, Murphy roths large lymphoproliferative mouse, Disease models, Monoclonal antibody, Article, Intercellular adhesion molecule 1 antibody, Brain metabolism, 03 medical and health sciences, Animal model, Rheumatology, Immunoglobulin, Genetic susceptibility, Genetics, Animals, Humans, Genetic Predisposition to Disease, Cyclophosphamide, Cytokine, Fisle 412 peptide, Autoantibodies, Immune mechanisms, Brain vasculitis, Disease model, business.industry, Mechanism (biology), Crry ig, Genetic predisposition, Targeted biological medication, Peptide fragment, Immunoregulation, Mental disease, Nonhuman, central nervous system, medicine.disease, Belimumab, Disease Models, Animal, Metabolism, 030104 developmental biology, Ribosomal p antibody, Nzbxnzw f1 mouse, Molecular targets, Hcdr1 peptide, Vitamin d, business, Cell phagocytosis, 030217 neurology & neurosurgery

    وصف الملف: application/pdf

  2. 2
    Review
  3. 3
  4. 4
    Academic Journal
  5. 5
  6. 6
    Electronic Resource

    المؤلفون: Chadban S.J., Atkins R.C.

    مصطلحات الفهرس: glomerulonephritis/dt [Drug Therapy], glomerulonephritis/ep [Epidemiology], glomerulonephritis/et [Etiology], glomerulonephritis/su [Surgery], glomerulonephritis/th [Therapy], glomerulosclerosis/dt [Drug Therapy], glomerulus filtration rate, Goodpasture syndrome/th [Therapy], hematuria, Heymann nephritis, human, hyperlipidemia/dt [Drug Therapy], immune system, immunoglobulin A nephropathy/dt [Drug Therapy], immunosuppressive treatment, infection/si [Side Effect], infection risk, infection sensitivity, inflammation, kidney biopsy, kidney cell, kidney disease, kidney failure/dt [Drug Therapy], cyclophosphamide/po [Oral Drug Administration], kidney transplantation, leukocyte, lung hemorrhage, lupus erythematosus nephritis/dt [Drug Therapy], membranoproliferative glomerulonephritis/dt [Drug Therapy], membranous glomerulonephritis/dt [Drug Therapy], minimal change glomerulonephritis/dt [Drug Therapy], nephrotic syndrome, nonhuman, pathogenesis, plasmapheresis, priority journal, protein restriction, proteinuria/si [Side Effect], rapidly progressive glomerulonephritis/dt [Drug Therapy], rapidly progressive glomerulonephritis/th [Therapy], risk assessment, sex ratio, side effect/si [Side Effect], T cell depletion, treatment outcome, vasculitis/dt [Drug Therapy], angiotensin receptor antagonist/dt [Drug Therapy], antibody/dt [Drug Therapy], dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy], hirudin/dt [Drug Therapy], hirudin/pd [Pharmacology], imatinib/dt [Drug Therapy], imatinib/pd [Pharmacology], immunosuppressive agent/ae [Adverse Drug Reaction], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/iv [Intravenous Drug Administration], antibody/pd [Pharmacology], antilipemic agent/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], azathioprine/pd [Pharmacology], CD20 antibody/dt [Drug Therapy], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/dt [Drug Therapy], chlorambucil/po [Oral Drug Administration], chlorambucil/pd [Pharmacology], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/dt [Drug Therapy], corticosteroid/pd [Pharmacology], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], immunosuppressive agent/po [Oral Drug Administration], immunosuppressive agent/pd [Pharmacology], intercellular adhesion molecule 1 antibody/dt [Drug Therapy], intercellular adhesion molecule 1 antibody/pd [Pharmacology], interleukin 1 receptor blocking agent/dt [Drug Therapy], interleukin 1 receptor blocking agent/pd [Pharmacology], interleukin 10/dt [Drug Therapy], interleukin 10/pd [Pharmacology], mycophenolic acid 2 morpholinoethyl ester/ae [Adverse Drug Reaction], mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy], mycophenolic acid 2 morpholinoethyl ester/pd [Pharmacology], n(g) nitroarginine methyl ester/dt [Drug Therapy], n(g) nitroarginine methyl ester/pd [Pharmacology], nitric oxide synthase inhibitor/dt [Drug Therapy], nitric oxide synthase inhibitor/pd [Pharmacology], oligonucleotide/dt [Drug Therapy], oligonucleotide/pd [Pharmacology], prednisone/do [Drug Dose], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rapamycin/ae [Adverse Drug Reaction], rapamycin/dt [Drug Therapy], rapamycin/pd [Pharmacology], steroid/dt [Drug Therapy], thrombin inhibitor/dt [Drug Therapy], thrombin inhibitor/pd [Pharmacology], unclassified drug, colony stimulating factor receptor antibody/dt [Drug Therapy], colony stimulating factor receptor antibody/pd [Pharmacology], monocyte chemotactic protein 1 antibody/dt [Drug Therapy], monocyte chemotactic protein 1 antibody/pd [Pharmacology], kidney failure/pc [Prevention], cyclophosphamide/pd [Pharmacology], cyclosporin/dt [Drug Therapy], acute kidney failure/si [Side Effect], Alport syndrome, antibody dependent cellular cytotoxicity, blood clotting, cancer susceptibility, cellular immunity, chronic glomerulonephritis, complement system, conference paper, diagnostic procedure, disease association, drug efficacy, drug induced cancer/si [Side Effect], drug safety, Conference Paper

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27330
    The Lancet
    Click here for full text options
    LibKey Link

  7. 7
    Electronic Resource
  8. 8
  9. 9
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33488
    Nephrology
    Click here for full text options
    LibKey Link